Donate For Public and Patients Store Search

F119 - Cutaneous Disorders of Pregnancy

Monday, March 4; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize important clinical features of pregnancy specific cutaneous disorders and potential fetal complications.
  • Formulate appropriate and safe topical and systemic therapies for pregnant patients with cutaneous disorders based on recent FDA guidelines and medical literature.
  • Develop appropriate management for pregnant patients with complex medical dermatology issues including cutaneous lupus erythematosus, psoriasis, and cutaneous malignancies based on current medical practice.


The recognition and management of pregnancy related cutaneous disorders can be challenging, along with potential impact on the fetus. Diagnostic clues in the recognition of these disorders, along with better appreciation of fetal compromise will be highlighted. Physiologic skin changes during pregnancy will be reviewed. Diseases with a Th2-immune response, such as lupus erythematosus, often flare during pregnancy and appropriate management will be reviewed. Challenging appropriate evaluation and management issues in the pregnant patient, including psoriasis and serious cutaneous malignancies, will be discussed. An overview of the safety guidelines for topical and systemic dermatologic therapy during pregnancy will be provided.


  • Bechtel, Mark A., MD: no financial relationships exist with commercial interests.
  • Kaffenberger, Jessica Amie, MD: AbbVie – I(Grants/Research Funding); AnaptysBio – I(Grants/Research Funding); Bristol-Myers Squibb – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Corrona, Inc. – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); XBiotech – I(Grants/Research Funding);
  • Pappas-Taffer, Lisa K., MD: no financial relationships exist with commercial interests.
  • Tyler, Kelly, MD: Celgene – I(Grants/Research Funding); Janssen Biotech – I(Grants/Research Funding); Lilly ICOS LLC – I(Grants/Research Funding);
  • Villasenor-Park, Jennifer, MD, PhD: no financial relationships exist with commercial interests.
Monday, March 4
9:00 AM
Dr. Bechtel and Dr. Kaffenberger / Introduction and Overview Pregnancy Dermatoses
9:30 AM
Dr. Tyler / Pregnancy and Medication Safety
9:50 AM
All faculty / questions
10:00 AM
Dr. Pappas-Taffer / Psoriasis and Autoimmune Connective Tissue Disease in the Pregnant Patient: Prognosis and Treatment
10:25 AM
Dr. Villasenor-Park / Melanoma/Non Melanoma Skin Cancer in Pregnancy: Prognosis and Treatment
10:50 AM
All faculty / questions
Event Details
  • Date
    Monday, March 4
  • Time
    9:00 AM - 11:00 AM
  • Location
    Room 102B
  • CME Credits
  • Type
  • Mark A. Bechtel, MD, FAAD
  • Kelly Tyler, MD, FAAD - Handout
  • Jennifer Villasenor-Park, MD, PhD, FAAD
  • Jessica Amie Kaffenberger, MD, FAAD
  • Lisa K. Pappas-Taffer, MD, FAAD